Company news

Telix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4E and 2022 Annual Report

February 27, 2023

2022 Full Year Results Release

February 27, 2023

Telix Full Year Results and Investor Conference Call Details

February 20, 2023

Q4 2022 Business update to accompany quarterly results

January 17, 2023

Appendix 4C and Activities Report - December 2022 Quarter

January 17, 2023

Webcast link correction - JP Morgan Conference Presentation

January 10, 2023

ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU

December 21, 2022

Telix Acquires Optimal Tracers

November 13, 2022

ZIRCON Ph III Imaging Study - Top-Line data presentation

November 6, 2022

ZIRCON Ph III Imaging Study - Positive Top-Line Results

November 6, 2022

Q3 2022 Business Update to accompany quarterly results

October 19, 2022

Appendix 4C and Activities Report - September 2022 Quarter

October 19, 2022

TLX250-CDx Indication Expansion - Preliminary Data

October 17, 2022

Expansion of partnership with GE Healthcare in PET imaging

October 16, 2022

Health Canada Approves Illuccix for Prostate Cancer Imaging

October 13, 2022

Chinese NMPA Approves TLX250 Phase III registration study

September 27, 2022

Telix Withdraws Marketing Application for Illuccix in Europe

September 27, 2022

Final IPAX-1 Study Data Confirms Safety Tolerability Profile

September 20, 2022

1H 2022 - Results Presentation

August 17, 2022

Appendix 4D - Results for announcement to the market

August 17, 2022

Grand Pharmaceutical Groups investment in Telix

August 14, 2022

APAC Regulatory Progress Prostate and Kidney Cancer Imaging

August 1, 2022

Appendix 4C and Activities Report for June 2022 Quarter

July 20, 2022

Kevin Richardson appointed as CEO, Telix Americas

July 10, 2022

Zircon Kidney Cancer Imaging Study completes Enrollment

July 10, 2022

Distribution Agreement with Isologic for Illuccix in Canada

June 22, 2022

Expansion of Partnership with RefleXion for Prostate Cancer

June 9, 2022

Telix receives AUD$17.25 million R&D tax refund

June 6, 2022

Leadership changes including Darren Smith appointment as CFO

May 31, 2022

Illuccix Reimbursement Milestone and Launch Updates

May 29, 2022

Appendix 4C and Activities Report for March 2022 quarter

April 21, 2022

ProstACT TARGET Phase II Study Ethics Approval

April 11, 2022

Telix Enters Licence Agreement with Lilly for Olaratumab

April 10, 2022

Telix, GMS & Monash Awarded $23 million Federal Funding

April 4, 2022

Commercial Launch - Illuccix Now Available to Order in US

April 3, 2022

FDA Orphan Drug Designation for Bone Marrow Conditioning

March 29, 2022

Telix and Xiel Sign U.K. and Ireland Distribution Agreement

March 28, 2022

Development of Glioblastoma Therapy Program

March 22, 2022

Radiopharmaceutical Production Facility Buildout Commences

March 21, 2022

ZIRCON Phase 3 Imaging Study Completes Targets Enrolment

March 7, 2022

Cancellation of Share Purchase Plan

March 1, 2022

2021 Full Year Results Presentation

February 23, 2022

Commercial Distribution Agreement for Illuccix for Australia

February 15, 2022

Telix Granted Illuccix EU Regulatory Review Extension

February 6, 2022

Sydney Airport to be removed from the S&P/ASX 200 Index

February 3, 2022

1st Patient Dosed ProstACT Prostate Cancer Therapy Program

January 26, 2022

Appendix 4C and Activities Report for December 2021 Quarter

January 23, 2022

Capital Raise Presentation

January 23, 2022

Telix completes $175M placement and launches $25M SPP

January 23, 2022

Targeted Alpha Therapy for Bladder Cancer 1st patient dosed

December 20, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 57 decks. Every deck is listed under its year.